Date: 2014-03-18
Type of information:
phase: preclinical
Announcement: results
Company: Galapagos (Belgium)
Product: GLPG1790
Action mechanism: GLPG1790 is a selective small molecule inhibitor of the ephrin receptor kinase family
Disease: triple-negative breast cancer
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest
news: * On March 18, 2014, Galapagos has announced it will present pre-clinical data on GLPG1790 in triple-negative breast cancer at the American Association for Cancer Research (AACR) Annual Meeting in San Diego on 7 April 2014. In the abstract, Galapagos disclosed that GLPG1790 is the first selective small molecule inhibitor of the ephrin receptor kinase family, which could play a key role in melanoma, pancreatic, ovarian, prostatic, and colorectal cancers, in addition to triple-negative breast cancer.Candidate drug GLPG1790 shows remarkable in vivo efficacy in a triple negative breast cancer xenograft pre-clinical model. Full tumor blockage was observed after 30 mg/kg/d oral dosing, correlated with target inhibition in the tumor. Extensive molecular mode of action studies, using GLPG1790 and knock-down tools, prove EPHA2 target engagement and impact on the MAPK pathway and cell cycle, important elements of the biology of many cancer types. GLPG1790 has good drug-like properties, and safety/tolerability studies with the candidate drug look favorable. Galapagos is completing preclinical studies with GLPG1790, and is carefully considering a number of options before entering the first clinical trials in humans. This novel program is fully proprietary to Galapagos.
